Synergistic Combinations of Paclitaxel and Withaferin a Against Human Non-Small Cell Lung Cancer Cells

Oncotarget - United States
doi 10.18632/oncotarget.27519
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Vorinostat Increases Carboplatin and Paclitaxel Activity in Non-Small Cell Lung Cancer Cells

International Journal of Cancer
Cancer ResearchOncology
2010English

P3.01-15 Efficacy of Paclitaxel Plus TS1 Against Non-Small Cell Lung Cancer Previously Treated

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Identification of Withaferin a as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer

Cancers
Cancer ResearchOncology
2019English

Single‐Agent Paclitaxel in the Treatment of Advanced Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
1999English

Cancer Stem Cells in Lung Cancer: Distinct Differences Between Small Cell and Non-Small Cell Lung Carcinomas

2011English

Dose-Finding and Sequencing Study of Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
1996English

Constitutive Androstane Receptor Ligands Modulate the Anti-Tumor Efficacy of Paclitaxel in Non-Small Cell Lung Cancer Cells

PLoS ONE
Multidisciplinary
2014English

Amplifying Outcomes: Checkpoint Inhibitor Combinations in First‐Line Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients With Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy